Type 2 diabetes: Prescription patterns and treatment outcomes of IDMPS survey in Argentina

José, Gagliardino Juan; Jorge, Elgart; Forti, L; Querzoli, Ivanna; Chantelot, Jean-Marc

doi:10.1016/j.diabres.2019.05.008

Cited by 4 publications

(4 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These original findings from developing countries concur with other reports based on IDMPS data [14,20], and are in line with data from developed countries indicating poor rates of glycaemic goal attainment (<53 mmol/mol [<7%];~20-40%) [21,22], indicating that the challenge of attaining good glycaemic control is universal. It is concerning that glycaemic control remains poor, given the increased use of insulin over time; it should be noted that the insulin dose of 0.3-0.7 U/kg was comparable if not higher than that used in clinical trial settings [23][24][25].…”

Section: Discussionsupporting

confidence: 88%

Persistent poor glycaemic control in individuals with type 2 diabetes in developing countries: 12 years of real-world evidence of the International Diabetes Management Practices Study (IDMPS)

et al. 2020

View full text Add to dashboard Cite

Aims/hypothesis We evaluated the secular trend of glycaemic control in individuals with type 2 diabetes in developing countries, where data are limited. Methods The International Diabetes Management Practices Study provides real-world evidence of patient profiles and diabetes care practices in developing countries in seven cross-sectional waves (2005-2017). At each wave, each physician collected data from ten consecutive participants with type 2 diabetes during a 2 week period. The primary objective of this analysis was to evaluate trends of glycaemic control over time. Results A total of 66,088 individuals with type 2 diabetes were recruited by 6099 physicians from 49 countries. The proportion of participants with HbA 1c <53 mmol/mol (<7%) decreased from 36% in wave 1 (2005) to 30.1% in wave 7 (2017) (p < 0.0001). Compared with wave 1, the adjusted ORs of attaining HbA 1c ≤64 mmol/mol (≤8%) decreased significantly in waves 2, 5, 6 and 7 (p < 0.05). Over 80% of participants received oral glucose-lowering drugs, with declining use of sulfonylureas. Insulin use increased from 32.8% (wave 1) to 41.2% (wave 7) (p < 0.0001). The corresponding time to insulin initiation (mean ± SD) changed from 8.4 ± 6.9 in wave 1 to 8.3 ± 6.6 years in wave 7, while daily insulin dosage ranged from 0.39 ± 0.21 U/kg (wave 1) to 0.33 ± 0.19 U/kg (wave 7) for basal regimen and 0.70 ± 0.34 U/kg (wave 1) to 0.77 ± 0.33 (wave 7) U/kg for basal-bolus regimen. An increasing proportion of participants had ≥2 HbA 1c measurements within 12 months of enrolment (from 61.8% to 92.9%), and the proportion of participants receiving diabetes education (mainly delivered by physicians) also increased from 59.0% to 78.3%. Conclusions In developing countries, glycaemic control in individuals with type 2 diabetes remained suboptimal over a 12 year period, indicating a need for system changes and better organisation of care to improve self-management and attainment of treatment goals.

show abstract

Section: Discussionsupporting

confidence: 88%

Persistent poor glycaemic control in individuals with type 2 diabetes in developing countries: 12 years of real-world evidence of the International Diabetes Management Practices Study (IDMPS)

et al. 2020

View full text Add to dashboard Cite

show abstract

“…In further specific analyses on types of non-insulin medication, the associations observed for T-stage and tumour grade remained in the group of patients using both metformin and SU medication, while no significant associations were observed in the metformin and SU only users. The type and number of medication used could be an indication for aggressivenes of diabetes phenotype and duration of having diabetes [ 26 ], as beta cell functioning decreases over time. People using multiple types of diabetes medication could potentially have worse glycaemic control compared to people only requiring one type of medication.…”

Section: Discussionmentioning

confidence: 99%

The Association between Diabetes Medication Use and Tumour Characteristics at Diagnosis in Patients with Urothelial Carcinoma: A Retrospective Registry-Based Study1

Faessen

Oerlemans

Jong

et al. 2023

BLC

View full text Add to dashboard Cite

BACKGROUND: Observational studies indicate a potential association between diabetes medication use and aggressiveness of bladder cancer. OBJECTIVE: The objective is to exploratively study the association between diabetes medication use, as proxy for diabetes, and cancer characteristics of urothelial carcinoma at diagnosis. Furthermore, differences in associations between specific types of diabetes medication are studied. METHODS: The association between use of diabetes medication and urothelial carcinoma (UC) characteristics at diagnosis is studied. A retrospective registry-based study among UC patients in the Netherlands was performed for which two large linked registries from PHARMO and IKNL were used. Patients diagnosed with UC between 2000 and 2016 and no previous cancer were included in this study. UC patients using diabetes medication were matched on age and sex with subjects not using diabetes medication (ratio 1:2), resulting in 1,164 diabetes medication users and 2,318 non-users. Conditional logistic regression analysis was performed to determine odds ratios comparing cancer characteristics between different types of diabetes medication users to non-users. RESULTS: Noninsulin antidiabetic drugs (NIAD) use was associated with a muscle-invasive type of UC compared to non-users (OR = 1.31, 95% CI: 1.10–1.55 for T2+ versus Ta) as well as a poorly differentiated tumour (OR = 1.31, 95% CI: 1.07–1.59 for poorly versus well differentiated tumours). CONCLUSION: Users of diabetes medication are potentially more likely to be diagnosed with a more aggressive tumour than non-users; however, lifestyle factors could not be adjusted for.

show abstract

“…Previous results from the IDMPS have indicated close associations of glycaemic control with possession of blood glucose monitoring devices, SMBG and access to diabetes education [ 8 , 17 , 32 ]. In this analysis, patients with T1D who performed SMBG or self-adjusted insulin dosage and patients with T2D who owned a glucose meter were less likely to have discontinued their insulin therapy in the past.…”

Section: Discussionmentioning

confidence: 99%

One in Seven Insulin-Treated Patients in Developing Countries Reported Poor Persistence with Insulin Therapy: Real World Evidence from the Cross-Sectional International Diabetes Management Practices Study (IDMPS)

et al. 2021

View full text Add to dashboard Cite

Introduction: Although poor adherence to insulin is widely recognised, periodic discontinuation of insulin may cause more severe hyperglycaemia than poor adherence. We assessed persistence with insulin therapy in patients with type 1 (T1D) or type 2 diabetes (T2D) in developing countries and the reasons for insulin discontinuation. Methods: The International Diabetes Management Practices Study collected real-world data from developing countries in seven waves between 2005 and 2017. In Wave 7

show abstract

Type 2 diabetes: Prescription patterns and treatment outcomes of IDMPS survey in Argentina

Cited by 4 publications

References 31 publications

Persistent poor glycaemic control in individuals with type 2 diabetes in developing countries: 12 years of real-world evidence of the International Diabetes Management Practices Study (IDMPS)

Persistent poor glycaemic control in individuals with type 2 diabetes in developing countries: 12 years of real-world evidence of the International Diabetes Management Practices Study (IDMPS)

The Association between Diabetes Medication Use and Tumour Characteristics at Diagnosis in Patients with Urothelial Carcinoma: A Retrospective Registry-Based Study1

One in Seven Insulin-Treated Patients in Developing Countries Reported Poor Persistence with Insulin Therapy: Real World Evidence from the Cross-Sectional International Diabetes Management Practices Study (IDMPS)

Contact Info

Product

Resources

About